

---

# Biologics and Biosimilars Access and Traceability



# Project Overview

---



- **Summary:** In-depth research and review of Biologics and Biosimilars as it relates to **Healthcare Information Technology (HIT)**
- **Goal:** Develop **Best Practices** for information and data flows for electronic prescribing and patient records for Biologics and Biosimilars
- **Project Deliverables:**
  - Information Scan
  - Stakeholder Research and In-Depth Interviews and Discussions
  - Standards Research
  - Legislative Research


# Key Findings

---




- Enhancing the ability to trace outcomes back to biologics/biosimilars requires **alignment of multiple stakeholders**, all of whom hold patient safety in high regard but have a limited exposure to biologics/biosimilars
- Any efforts moving forward must be considered against a **prevailing mindset among many stakeholders to treat competitor biologic products exactly like multisource, single molecule drugs**
- There are workflows and processes that can be adapted to trace outcomes to biologics/biosimilars such as the tracking, tracing and reporting of vaccines, discontinuation of prescription and reporting and connecting to prescription drug monitoring programs\*. There is also legislation (DSQA/DSCSA) that can be leveraged. However, **regulations or legislation will be required to compel EHR users to report ADEs**
- The mapping of relevant information flows overlaid by existing standards reveals that **batch/lot # and manufacturer need to be added to a number of NCPDP and HL7 standards, and recorded in EHRs**. There is also a need for improved reporting of ADEs, some of which are being piloted.
- For biologics/biosimilars not administered in the practice, there are two transactions that could support getting this information back into the EHR – Medication History and RxFill. Of those, **RxFill has fewer challenges**.

# Information flows: Across all channels follow a flow




Information flow details and transactions to support patient care varies by the medication requirements for administration and payers requirements


# Information flows: Ambulatory Clinic




# Information flows: Specialty Pharmacy, Infusion Center



# Information flows: Hospital




# Information flows: Self Administered






# Information flows: Long-term or Post-Acute Care (1)

## Scenario One: Medication sourced from LTPAC pharmacy stock



# Information flows: Long-term or Post-Acute Care (2)

## Scenario Two: Medication obtained from a specialty pharmacy



Thank you



[www.pocp.com](http://www.pocp.com)